Literature DB >> 24105981

Metabolomics and the search for biomarkers in Parkinson's disease.

Amy W Amara1, David G Standaert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24105981      PMCID： PMC4050667          DOI： 10.1002/mds.25644

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  12 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  Defining at-risk populations for Parkinson's disease: lessons from ongoing studies.

Authors:  Daniela Berg; Ken Marek; George W Ross; Werner Poewe
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

3.  Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases.

Authors:  Walter Maetzler; Stefan P Schmid; Isabel Wurster; Inga Liepelt; Alexandra Gaenslen; Thomas Gasser; Daniela Berg
Journal:  Mov Disord       Date:  2010-09-14       Impact factor: 10.338

Review 4.  Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities.

Authors:  George D Mellick; Peter A Silburn; Greg T Sutherland; Gerhard A Siebert
Journal:  Expert Rev Mol Diagn       Date:  2010-11       Impact factor: 5.225

5.  Kynurenine pathway abnormalities in Parkinson's disease.

Authors:  T Ogawa; W R Matson; M F Beal; R H Myers; E D Bird; P Milbury; S Saso
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

6.  Metabolomic profiling to develop blood biomarkers for Parkinson's disease.

Authors:  Mikhail Bogdanov; Wayne R Matson; Lei Wang; Theodore Matson; Rachel Saunders-Pullman; Susan S Bressman; M Flint Beal
Journal:  Brain       Date:  2008-02       Impact factor: 13.501

Review 7.  Metabolomics tools for identifying biomarkers for neuropsychiatric diseases.

Authors:  Marlon P Quinones; Rima Kaddurah-Daouk
Journal:  Neurobiol Dis       Date:  2009-03-19       Impact factor: 5.996

Review 8.  Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.

Authors:  Manfred Gerlach; Walter Maetzler; Karl Broich; Harald Hampel; Lucas Rems; Torsten Reum; Peter Riederer; Albrecht Stöffler; Johannes Streffer; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-07-14       Impact factor: 3.575

9.  Metabolomic profiling in LRRK2-related Parkinson's disease.

Authors:  Krisztina K Johansen; Lei Wang; Jan O Aasly; Linda R White; Wayne R Matson; Claire Henchcliffe; M Flint Beal; Mikhail Bogdanov
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

Review 10.  Dysregulation of glutathione homeostasis in neurodegenerative diseases.

Authors:  William M Johnson; Amy L Wilson-Delfosse; John J Mieyal
Journal:  Nutrients       Date:  2012-10-09       Impact factor: 5.717
View more
  2 in total

1.  Long term conservation of human metabolic phenotypes and link to heritability.

Authors:  Noha A Yousri; Gabi Kastenmüller; Christian Gieger; So-Youn Shin; Idil Erte; Cristina Menni; Annette Peters; Christa Meisinger; Robert P Mohney; Thomas Illig; Jerzy Adamski; Nicole Soranzo; Tim D Spector; Karsten Suhre
Journal:  Metabolomics       Date:  2014-02-26       Impact factor: 4.290

2.  Recent Advances in Biomarkers for Parkinson's Disease.

Authors:  Runcheng He; Xinxiang Yan; Jifeng Guo; Qian Xu; Beisha Tang; Qiying Sun
Journal:  Front Aging Neurosci       Date:  2018-10-11       Impact factor: 5.750
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.